HERBAL NANOSUSPENSION: IN VITRO CANCER STUDY AGAINST DIFFERENT CELL LINES

MITHRA MM, KRISHNAKUMAR K, SMITHA K NAIR*
Department of Pharmaceutics, St. James’ College of Pharmaceutical Sciences, St. James’ Hospital Trust Pharmaceutical Research Centre (DSIR Recognized), Chalakudy, Kerala, India. Email: stjamespharmacyproject@gmail.com

Received: 05 April 2020, Revised and Accepted: 16 May 2020

ABSTRACT
Herbal formulations marketed in India for many years providing its therapeutic benefits in health problems. Medicinal plants or their phytoconstituents are less toxic and free from side effects than synthetic drugs. However, formulation aspects of these phytoconstituents are limited due to its low solubility. Nanotechnology is a promising technique to increase the solubility of herbal drugs. This will lead to a subsequent reduction in drug dose. Nanoformulations such as nanosuspension increase the solubility of poorly soluble drugs and also have good targeting effects on different cells. The efficacy of herbal nanosuspensions evaluated using different cell lines. Here, hepato cellular carcinoma cell line (SMMC-7721), human prostate cancer cell line, human myelogenous leukemia cell line, human epithelial cell line, human breast cancer cell lines (4T1, MCF-7, and MDA-MB-453), carcinomic human alveolar basal epithelial cell line (A549), human umbilical vein endothelial cell line, human colorectal adenocarcinoma cell line (HT-29), and human epithelial carcinoma cell line (HeLa) are used in the evaluation procedures. In vitro assays help in the determination of the dose range of drugs for the activity. The present review highlights the in vitro cancer studies of herbal nanosuspensions using different cell lines.

Keywords: Nanosuspension, Herbal, In vitro cell lines.

INTRODUCTION
Herbal medicines are used all over the world due to their low toxicity and reduced side effects than synthetic drugs [1]. The greater part of the active constituents of herbal extract is ineffective to pass lipid membranes due to their high molecular size or low solubility. Nanosuspension technology is introduced as a result of many efforts made by formulation scientists and emerged as a potent candidate for the delivery of the poorly soluble drugs in a more efficient manner. Hence, herbal extract in the form of nanosuspension may be beneficial for the treatment of various diseases [2].

In vitro bioassays are important in the evaluation of these herbal nanosuspensions with possible pharmacological effects [3]. Cell-based bioassays are used to find the pharmacological activity of formulations, and for this purpose, it requires identification of a responsive cell line. A cell line can proliferate indefinitely in an appropriate fresh medium and space. These have a major role in studying physiological, pathophysiological, and differentiation process of exact cells [4]. The cell lines possess many characteristics of normal cells, so these are used in the studies to determine whether medicinal plants have defined pharmacological activities [5].

TYPES OF CELL LINES
Finite cell lines
The cell in culture divides only a limited number of times before their growth rate decreases, and finally, they will die. The cell lines with limited culture life spans are known as finite cell lines. The cells normally divide 20–100 times before destruction. The human cells divide 50–100 times.

Continuous cell lines
A few cells in culture may get different morphology and get modified. Such types of cells are capable of growing faster and resulting in an independent culture. The progeny obtained from these modified cells have an unlimited life. They are known as continuous cell lines. These are transformed, immortal, and tumorigenic.

SELECTION OF CELL LINE
Species
Species differences are important while extrapolating the data to humans.

Finite or continues cell lines
Cultures with continuous cell lines are preferred due to their high yield.

Normal or transformed cells
The transformed cells are preferred because they are immortalized and grow quickly.

Availability
It may be produced in the laboratory.

Stability
The stability of a cell line related to cloning and storage.

Growth characteristics
- Population doubling time
- Ability to grow in suspension
- Saturation density
- Cloning efficiency [6].

IN VITRO CANCER CELL LINE STUDY
In vitro evaluation of curcumin nanosuspension against HeLa cell lines
Curcumin is the active ingredient present in the plant turmeric (Curcuma longa) [7], and it has a wide range of pharmacological activities including anti-cancer, anticoagulant, antimicrobial, antioxidation, and antiproliferation [8]. Curcumin used to treat the regression of psoriasis, pre-malignant lesions of the bladder, also the treatment of many cancers such as the cervix, soft palate, stomach, colorectal, and skin cancers [9-13]. Curcumin can be considered as a prospective drug due to its high safety and low cost [1-4].

HeLa cell lines are the most commonly used human immortal cell lines [15]; originally, it was reported from a female African-American
individual in 1952 as a cervical epithelial carcinoma, consequent analysis of tumor pathology, and clinical phenotype identified the first tumor as an uncommon adenocarcinoma [16]. Hela has a powerful adaptation to culture conditions because it was the first cell line widely cultured [17]. It is epithelial in appearance grows fast with a doubling time of 24 h and shows a scarcity of contact inhibition [18]. These cells can proliferate rapidly compared to other cancer cells [19]. The stable growth of Hela enabled the development of the polio vaccine [20], and also it is used by scientists in different types of investigations such as disease research, gene mapping, effects of toxic substances in organisms, and radiation on humans [21].

The anticancer activity of curcumin nanosuspension was assessed by MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method. The Hela cells were exposed to curcumin nanosuspension and free curcumin solution at different concentrations (5, 10, 20, 40, 80, 160 µg/ml) for 3 days. Empty expensives as negative control were added at equivalent concentrations as that within the tested curcumin nanosuspension. The curcumin nanosuspension and free curcumin solution inhibited the growth rate of tumor cells in a dose-dependent manner. This study suggested that curcumin nanosuspension shows higher anticancer activity than free curcumin at the same concentration due to the presence of nano-sized particles [22].

**In vitro evaluation of silybin nanosuspension against prostate cancer cell lines (PC-3) and human epithelial cell line (Caco-2) cell lines**

Silybin is a chemical constituent isolated from milk thistle plant (*Silybum marianum*) and used as a therapeutic agent for a variety of diseases, including human colon cancer, liver disease, and prostate cancer. It also suppresses the cell growth and DNA synthesis, and it is chemopreventive targeting inhibit the invasive process in prostate cancer [23–25]. This herb can be used in beta-thalassemia patients due to its immunomodulatory, anti-inflammatory, and antioxidant properties [26,27].

PC3 cell lines are human prostatic adenocarcinoma cell line that is used in prostatic adenocarcinoma research and drug development. These were isolated from bone metastasis and grew as an adherent layer [28]. It helps to determine biochemical changes in advanced prostate cancer cells and assessing their response to chemotherapeutic agents [29]. Other PC3-3 such as DU145 and LNCap have low metastatic potential compared to PC-3 cell lines [30]. Protein expression of PC-3 cells may be a characteristic of small cell neuroendocrine carcinoma [31]. For the generation of subcutaneous tumor xenografts in mice, these cell lines can act as a good tool. Hence, it helps to investigate the tumor environment and therapeutic drug functionality [32].

Antitumor effect of prepared silybin nanosuspension and free silybin was assayed against the PC-3 cell line in an *in vitro* model and evaluated at different concentrations (0.2, 1, 2, 10, 20, and 100 µg/ml) for 12, 24, 3, and 48 h by MTT reduction assay. The inhibition rate of silybin nanosuspension to PC-3 cells increased with the concentration and time. This study suggested that silybin nanosuspension shows a higher inhibition rate than free silybin at the same concentration [33].

Caco-2 cell line originates from the human colon adenocarcinoma tissue, and it forms a monolayer of polarized enterocytes through spontaneous cellular differentiation. Caco-2 cells are shown to express many enzymes and display all of the four different transport routes of the intestinal epithelium [34]. Furthermore, the Caco-2 monolayer is a good *in vitro* model of human small intestine mucosa [35].

The anticancer activity of silybin nanosuspension against the Caco-2 cell line was determined by MTT assay. It was performed to measure the cellular viability. For the study, cell lines were incubated with silybin formulations for 3, 6, 9, and 12 h at a concentration range of 10–500 µg/ml. When the concentration of silybin was below 125 µg/ml, there was no significant difference between the experimental group and the control group. Hence, this study was stated that nanosuspensions were related to no cytotoxic below the concentration of 125 µg/ml [36].

**In vitro evaluation of oridonin nanosuspension against human myelogenous leukemia cell line (K562) and SMMC-7721 cell lines**

Oridonin is a natural ent-kaurane diterpenoid extracted from the various plants such as Isodon trigocarpus, Isodon japonicas, and Isodon shikokium [37–39]. It has various pharmacological effects including anti-inflammatory, anti-bacterial, and anti-tumor activity. Mainly, it is used to treat human cancers, including prostate cancer, breast cancer, and lung cancer [40–42].

K562 cell lines are myelogenous leukemia cell lines that produce less clumping in culture due to the downregulation of surface adhesion molecules by the fusion gene [43]. The cells are non-adherent and round; also, it shows a proteomic resemblance to undifferentiated granulocytes [44] and erythrocytes [45]. They easily destroyed by natural killer cells [46] because they lack the major histocompatibility complex required to inhibit natural killer cell activity [47].

The *in vitro* anticancer activity of oridonin nanosuspension against K562 cell was determined by MTT assay at different concentrations of oridonin nanosuspension and free oridonin solution (5, 10, 20, 30, and 40 µmol/l). The incubation time was 12, 18, 24, and 36 h. The anticancer activity of oridonin nanosuspension increases with the concentration and incubation time. This study suggested that the oridonin nanosuspension shows more anticancer activity than a free oridonin solution at the same concentration. Moreover, this enhanced effect due to the presence of nanoparticles [48].

The SMMC-7721 cell line was derived in 1977 from hepatocellular carcinoma patients. This cell line expresses two receptors, that is, epidermal growth factor receptor and vascular endothelial growth factor receptor. It is an useful tool in liver cancer research [49].

MTT assay was used to determine the *in vitro* anticancer activity of the oridonin nanosuspension compared to the free oridonin solution against the SMMC-7721 cell line. The different concentrations (5, 10, 20, 30, and 40 µmol/l) of oridonin nanosuspension and the free oridonin solution used for the cell line study. The incubation period was 12, 24, 36, and 48 h. Both nanosuspension and free solution inhibited the growth of SMMC-7721 cells in a time-dose-dependent manner. This study suggested that at the same concentration, oridonin nanosuspension showed a higher inhibition rate against SMMC-7721 cell line than a free oridonin solution. It may be due to the presence of a high concentration of free oridonin or uptake of nanoparticles or the combination of both [50].

**In vitro evaluation of gambogenic acid nanosuspension against hepatocellular carcinoma cell line (HepG2) cell line**

Gamboge is a herbal medicine derived from *Garcinia hanburyi* tree, and it shows pharmacological activities such as detoxification, anti-inflammatory, and parasiticide effects. The main active constituent present in the plant includes gambogenic acid and gamboge. Gambogenic acid has a broad-spectrum anti-tumor effect in different cancer cell lines [51,52].

HepG2 is a human liver cancer cell line isolated from the liver tissues. This immortal cell line used in drug metabolism and hepatotoxicity studies [53,54]. These cells are epithelial in morphology, and various proteins such as albumin, fibrinogen, transferrin, and plasminogen are secreted from these HepG2 cell lines [55]. At suitable culture conditions, HepG2 cell lines show robust morphological and functional differentiation [56]. These are good *in vitro* model system for the study of intracellular trafficking, dynamics of bile canalicular, sinusoidal membrane proteins, and lipids in human hepatocytes [57].

The anti-tumor activity of gambogenic acid nanosuspension on the HepG2 cell line was determined by MTT assay. The HepG2 cell line...
was exposed to different concentrations (0.5, 1, 2, 4, 8, and 16 µM) of gambogenic acid nanosuspension and free gambogenic acid solution for 48 h. The cytotoxicity of the gambogenic acid solution and gambogenic acid nanosuspension depends on the dose and concentration rate. This study suggested that the gambogenic acid nanosuspension has significant cytotoxicity to HepG2 cells than a gambogenic acid solution at an equivalent dose and it may be due to uptake of nanoparticles [58].

**In vitro evaluation of Genkwanin nanosuspension against 4T1, MCF-7, MDA-MB-453, A549, and human umbilical vein endothelial cell line (HUVEC) cell lines**

Genkwanin is a flavonoid isolated from Genkwa flos, Rosmarinus officinalis [59], and the leaves of Cistus laurifolius [60]. It is known as a representative marker for quality control of traditional Chinese prescriptions [61]. It has various pharmacological effects, including anti-inflammatory, anti-plasmodial [64], anti-bacterial [63], anti-platelet aggregation [86], radical scavenging [65], chemoprotective [66], and inhibiting 17β-hydroxysteroid dehydrogenase type 1 activities [67].

4T1 is a breast cancer cell line isolated from the mammary gland tissue of the mouse. These epithelial cells are resistant to 6-thioguanine [68]. It is mainly used to study breast cancer metastasis [69], and in live tissues, it is highly aggressive [70].

The MCF-7 is a breast cancer cell line isolated from Caucasian women [71,72] and acronym of Michigan cancer foundation-7 [73]. This noninvasive cell line represents a model of early-stage disease [74].

MDA-MB-453 cell line is a human breast cancer cell line and it has an active glycerol-3-phosphate shuttle [75].

A549 cells are human epithelial cell lines developed in 1972 [76]. These types of cell lines are human alveolar basal epithelial cells [77]. These cell lines used for the study of lung cancer and also used for developing a drug against lung cancer [78,79]. It is responsible for the diffusion of water and electrolytes across alveoli. It is widely used as a type 2 pulmonary epithelial cell model for drug metabolism [80]. It is employed in viral research and also been studied for cell line response to tuberculosis [81,82].

HUVEC cell lines are derived from human umbilical vein endothelial cells in the 1970s and used as a laboratory model system for the study of the function and pathology of endothelial cells [83,84].

Anticancer activity of Genkwanin nanosuspension and Genkwanin solution against 4T1, MCF-7, MDA-MB-453, A549, and HUVEC cell lines assessed using MTT assay. Various concentrations (0.5, 1, 2, 4, 8, and 16 µg/ml) of Genkwanin nanosuspension and Genkwanin solution were used for the study. The incubation time was 48 h. Both Genkwanin nanosuspension and Genkwanin solution inhibited cell proliferation in a dose-dependent way. This study suggested that Genkwanin nanosuspension exhibited higher cytotoxicity than the Genkwanin solution against all studied cell lines [85].

**In vitro evaluation of puerarin nanosuspension against HT-29 cell line**

Puerarin is an isoflavone [86] isolated from the root of Pueraria lobata [87]. It has many beneficial effects on liver diseases [88,89], cardiovascular [90,91], neurological [92,93], anti-platelet aggregation [94], and hyperglycemic disorders [95]. Furthermore, it exhibits protective actions against fever, inflammation, hyperlipidemia, osteonecrosis, and oxidative damage [96].

HT-29 cells are a colon cancer cell line utilized in cancer research [97]. These cells are useful for somatic cell research due to their ability to differentiate and simulate real colon tissue in vitro [98]. HT-29 cells can proliferate in cell culture with a doubling time of around 4 days without using the growth factors. The doubling time is often reduced to 1 day with added fetal bovine serum [99]. The HT-29 cells have shown induced differentiation [100], with galactose-mediated differentiation, also results in the strengthening of adherens junctions [101].

The antitumor activity of puerarin nanosuspension was evaluated by MTT assay. Various concentrations (1.25, 2.5, 12.5, and 25 µg/ml) of puerarin nanosuspension and puerarin solution incubated for 8, 16, and 24 h. Both the puerarin nanosuspension and puerarin solution inhibited the cell proliferation of HT-29 in a concentration time-dependent manner. This study suggested that compared with puerarin free solution, nanosuspension of puerarin showed a significant increase in the cell inhibition rates under the same concentrations. The inhibitory effects increased with concentration and incubation time [102].

**CONCLUSION**

Herbal drugs have low side effects than synthetic drugs and also if it is formulated as nanosuspensions that it increases the solubility of drugs than conventional dosage forms. For the *in vitro* evaluation of herbal nanosuspensions, cell lines are mostly preferred. Because it offers easy, inexpensive, and stable platforms for the study. Here, HepG2, PC-3, K562, Caco-2, SMCC-7721, 4T1, MCF-7, MDA-MB-453, A549, HUVEC, HT-29, and HeLa cell lines are used in the evaluation of different herbal nanosuspensions. Each cell line is derived from various organs and sources. MTT assays are the most commonly used method in the cell line studies to estimate the number of viable cells in multi-well plates. Cell metabolic activity can be determined using this assay method. Hence, cell lines can be used as an *in vitro* model for evaluation of herbal nanosuspensions.

**AUTHORS’ CONTRIBUTIONS**

The authors declare that this work was done by the authors named in this article.

**CONFLICTS OF INTEREST**

There are no conflicts of interest.

**AUTHOR’S FUNDING**

Self-funding

**REFERENCES**

1. Mishra SB, Pandey H, Pandey AC. Nanosuspension of *Phyllanthus amarus* extract for improving oral bioavailability and prevention of paracetamol induced hepatotoxicity in Sprague-Dawly rats. Adv Nat Sci Nanotechnol 2013;4:1-6.

2. Jahan N, Aslam S, Rahman UK, Fazal T, Anwar F, Saher F. Formulation and characterization of nanosuspension of herbal extract for enhanced antiradical potential. J Exp Nanosci 2015;11:72-80.

3. Duthie SJ, Melvin WT, Burke MD. Bromobenzene detoxification in the human liver-derived HepG2 cell line. Xenobiotica 1994;24:265-79.

4. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/cell-line.

5. Pareek A, Godavarthi A, Issarani R, Nagori BP. Antioxidant and hepatoprotective activity of Fagonia schweinfurthii (Hadidi) Hadidi extract in carbon tetrachloride induced hepatotoxicity in HepG2 cell line and rats. J Ethnopharmacol 2013;150:973-81.

6. Available from: http://www.biologydiscussion.com/cell/cell-lines/cell-lines-types-nomenclature-selection-and-maintenance-with-statistics/10517.

7. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Gockner J, et al. Curcumin a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004;304:600-2.

8. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007;4:807-18.

9. Kuttan R, Sudheeran PC, Joseph CD. Turmeric and curcumin as topical agents in cancer therapy. Tumori 1987;73:29-31.

10. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase 1 clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900. 

27
Sharma RA, Euden SA, Platten SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847-54.

Kurd SK, Smith N, Van VA, Troxel AB, Badmaev V, Seykora JT, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol 2008;58:625-31.

Singh M, Singh N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem 2009;325:107-17.

Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:80-99.

Rahbari R, Shirvani T, Modes V, Collier P, Macfarlane C, Badge RM. A novel L1 retrotransposon marker for HeLa cell line identification. Biotechniques 2009;46:277-84.

Masters JR. HeLa cells 50 years on: The good, the bad and the ugly. Nat Rev Cancer 2002;2:315-9.

MacLeod RA, Dirks WG, Matsuo Y, Kaufmann M, Milch H, Drexler HG. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999;83:555-63.

Stephenson EM. Locomotory invasion of human cervical epithelial and avian fibroblasts by HeLa cells in vitro. J Cell Sci 1982;57:293-314.

Available from: https://www.nobelprize.org/prizes/medicine/2009/press-release.

Available from: https://www.vansmith.me/2017/11/12/wonder-women-in-sciences-press-release.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.nobelprize.org/prizes/medicine/2009/press-release.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.vansmith.me/2017/11/12/wonder-women-in-sciences-press-release.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.

Available from: https://www.readycell.com/cacoready.
63. Martini ND, Katerere DR, Eloff JN. Biological activity of five antibacterial flavonoids from Combretum erythrophyllum (Combretaceae). J Ethnopharmacol 2004;93:207-12.

64. Kraft C, Chien K, Sienna K, Jakupovic J, Mavi S, Bienzle U, et al. In vitro antiproliferation evaluation of medicinal plants from Zimbabwe. Phytother Res 2003;17:123-8.

65. Kim AR, Zou YN, Park TH, Shim KH, Kim MS, Kim ND, et al. Active components from Artemisia twaymoggi displaying ONOO(-) scavenging activity. Phytother Res 2004;18:1-7.

66. Suh N, Luyengi L, Fong HH, Kinghorn AD, Pezzuto JM. Discovery and characterization of the A549 cell line as a Type II pulmonary epithelial cell line in response to exhaust particles in human A549 lung cells and murine RAW264.7 cells. Methods Mol Biol 2012;928:221-8.

67. Brozic P, Kocbek P, Sova M, Kristl J, Martens S, Adamski J, et al. Activity, pharmacophore modeling, and QSAR studies of novel pyrazoles of natural product chemopreventive agents utilizing HL-60 cell differentiation as a model. Anticancer Res 1995;15:233-9.

68. Brozinick JT, Berk DL, Lai E, Stachura DP, et al. Androgen-responsive human breast carcinoma cell line with high level of heme oxygenase-1. J Nutr Biochem 2012;23:1080-5.

69. Liu XJ, Zhao J, Gu XY. The effects of genistein and puercarin on the activation of nuclear factor-kappaB and the production of tumor necrosis factor-alpha in HT29: Autocrine growth and deregulated expression of the c-myc oncogene. Cancer Res 1989;49:6566-71.

70. Xiao C, Li J, Dong X, He X, Niu X, Liu C, et al. Anti-oxidative and TNF-alpha suppressive activities of puercarin derivative (4AC) in RAW264.7 cells and collagen-induced arthritic rats. Eur J Pharmacol 2011;666:242-50.

71. Wu L, Qiao H, Li Y, Li L. Cardioprotective effects of the combined use of puercarin and danshensu on acute ischemic myocardial injury in rats. Phytother Res 2011;25:751-6.

72. Zhang SY, Chen G, Wei PF, Huang XS, Dai Y, Shen YJ, et al. The effects of puercarin on serum nitric oxide concentration and myocardial eNOS expression in rats with myocardial infarction. J Asian Natl Prod Inst 2008;301:229-34.

73. Yang S, Zhang J, Huang XY. Mouse models for tumor metastasis. Methods Mol Biol 2012;928:221-8.

74. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

75. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level of heme oxygenase-1. J Nutr Biochem 2012;23:1080-5.

76. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

77. Kao J, Salari K, Bocanegra M. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2014;9:e98624.

78. Kao J, Salari K, Bocanegra M. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2014;9:e98624.

79. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level of heme oxygenase-1. J Nutr Biochem 2012;23:1080-5.

80. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

81. Kim AR, Zou YN, Park TH, Shim KH, Kim MS, Kim ND, et al. Active components from Artemisia twaymoggi displaying ONOO(-) scavenging activity. Phytother Res 2004;18:1-7.

82. Brozinick JT, Berk DL, Lai E, Stachura DP, et al. Androgen-responsive human breast carcinoma cell line with high level of heme oxygenase-1. J Nutr Biochem 2012;23:1080-5.

83. Liu XJ, Zhao J, Gu XY. The effects of genistein and puercarin on the activation of nuclear factor-kappaB and the production of tumor necrosis factor-alpha in HT29: Autocrine growth and deregulated expression of the c-myc oncogene. Cancer Res 1989;49:6566-71.

84. Zhao Y, Yang Y, Sun Y, Shen Y, Huang XY. The effects of puercarin on serum nitric oxide concentration and myocardial eNOS expression in rats with myocardial infarction. J Asian Natl Prod Inst 2008;301:229-34.

85. Yang S, Zhang J, Huang XY. Mouse models for tumor metastasis. Methods Mol Biol 2012;928:221-8.

86. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

87. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level of heme oxygenase-1. J Nutr Biochem 2012;23:1080-5.

88. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

89. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level of heme oxygenase-1. J Nutr Biochem 2012;23:1080-5.

90. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

91. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level of heme oxygenase-1. J Nutr Biochem 2012;23:1080-5.

92. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

93. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level of heme oxygenase-1. J Nutr Biochem 2012;23:1080-5.

94. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

95. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level of heme oxygenase-1. J Nutr Biochem 2012;23:1080-5.

96. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

97. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.

98. Bryan D, Thorpe JE, Disch BC, Bastian A, Hauser PJ, Farasyn T, et al. A novel and potential antitumor drug in breast carcinoma therapy. Drug Deliv 2017;24:1491-500.